AMG 386 in Combination With Sorafenib in Patients With Metastatic Clear Cell Carcinoma of the Kidney: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study

BACKGROUND: This study evaluated the tolerability and antitumor activity of AMG 386, a peptibody (a peptide Fc fusion) that neutralizes the interaction of angiopoietin-1 and angiopoietin-2 with Tie2 (tyrosine kinase with immunoglobulin-like and EGF-like domains 2), plus sorafenib in patients with cl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Rini, Brian, Szczylik, Cezary, Tannir, Nizar M., Koralewski, Piotr, Tomczak, Piotr, Deptala, Andrzej, Dirix, Luc Y., Fishman, Mayer, Ramlau, Rodryg, Ravaud, Alain, Rogowski, Wojciech, Kracht, Karolyn, Sun, Yu-Nien, Bass, Michael B., Puhlmann, Markus, Escudier, Bernard
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4666535/
https://ncbi.nlm.nih.gov/pubmed/22692704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.27632
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados